Previous 10 | Next 10 |
AbbVie (NYSE: ABBV ) and licensor Neurocrine Biosciences (NASDAQ: NBIX ) announce the commercial availability of the 200 mg twice-daily regimen (for up to six months) of ORILISSA (elagolix) for the treatment of moderate to severe pain associated with endometriosis. More news on: AbbVie...
Amgen (NASDAQ: AMGN ) resumed with Outperform rating and $208 (24% upside) price target at Credit Suisse. More news on: Amgen Inc., Biogen Inc., Gilead Sciences, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma...
SAN DIEGO , May 20, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced new data from RE-KINECT, the largest real-world screening study to date of patients with clinician-confirmed possible tardive dyskinesia (TD), demonstrating the effect of involuntary ...
SAN DIEGO , May 16, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it will present a new quality-of-life data analysis from RE-KINECT, the largest real-world screening study of patients with clinician-confirmed possible tardive dyskinesia (TD...
SAN DIEGO , May 7, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2019 at 10:00 a.m. PT ( 1:00 p.m. ET ) on Tuesday, May 14, 2019 , in Las Vegas . Kevin Gorman , Chief Executive Officer, a...
Catalyst Pharmaceuticals ( CPRX ) - As I'm writing this, the stock has lost 40% of its value in a single day after news came that the FDA approved Ruzurgi from Jacobus Pharma for LEMS (Lambert-Eaton myasthenic syndrome) patients age six to less than 17 years of age. This is the first app...
Results from two Phase 3 clinical trials evaluating Neurocrine Biosciences' ( NBIX +0.4% ) opicapone in Parkinson's disease (PD) patients showed a treatment effect. The data were presented at the American Academy of Neurology Annual Meeting in Philadelphia. More news on: Neurocrine Bi...
SAN DIEGO , May 6, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its support of Mental Health Month and commitment to raising awareness of tardive dyskinesia (TD), an involuntary movement disorder. 1 May marks the 70 th anniversary of Mental Health Mon...
Neurocrine Biosciences (NASDAQ: NBIX ) and Voyager Therapeutics (NASDAQ: VYGR ) reports Phase I trial results for VY-AADC from eight patients with Parkinson’s disease. These Phase I results were presented at the 2019 American Academy of Neurology (AAN) Annual Meeting. More news on...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...